
Encompass Health (EHC) Stock Forecast & Price Target
Encompass Health (EHC) Analyst Ratings
Bulls say
Encompass Health Corp has demonstrated a positive upward trend in revenue guidance, with the high-end of forecasts increasing from $1.065 billion to $1.090 billion for 2024, and from $910 million to $950 million for 2023, indicating robust growth expectations. Furthermore, the company has successfully increased its Medicare Advantage (MA) payer mix from approximately 9.2% in 2018 to around 16.5% by the first quarter of 2025, reflecting a significant shift in its business strategy that aligns with market demand. This combination of increasing revenue guidance and an expanding MA book of business positions Encompass Health favorably within the post-acute healthcare sector.
Bears say
Encompass Health Corp's outlook appears negative due to the anticipated challenges associated with its de novo and joint venture strategies, which may lead to increased construction and labor costs amid rising tariffs and competitive labor markets. The company could face difficulties in staffing new facilities, which is critical for achieving mature operating levels, potentially disrupting its earnings profile. Given these factors, there are significant risks that could impede the company's ability to meet projected financial targets, including its 2025 adjusted EBITDA goal of $1.245 billion.
This aggregate rating is based on analysts' research of Encompass Health and is not a guaranteed prediction by Public.com or investment advice.
Encompass Health (EHC) Analyst Forecast & Price Prediction
Start investing in Encompass Health (EHC)
Order type
Buy in
Order amount
Est. shares
0 shares